oncology
GU Cancer

Cabozantinib shows promising effects on brain metastases in RCC

The tyrosine kinase inhibitor cabozantinib has shown promising activity against brain metastases in patients with renal cell carcinoma (RCC), achieving a 50% response rate, according to US researchers. A retrospective cohort study involving 88 patients with metastatic RCC and brain metastases treated in 15 international institutions showed that cabozantinib could potentially pass through the blood-brain ...

Already a member?

Login to keep reading.


OR
© 2022 the limbic